Skip to Content
Global News Select

Zoetis Posts Higher 2Q Profit, Raises Fiscal Year Outlook

By Dave Sebastian

Zoetis Inc. said its profit rose for the recent quarter and raised its profit and revenue guidance for the full year as it continues to cater to pet care amid the Covid-19 pandemic.

The Parsippany, N.J.-based company, which makes vaccines and medication for livestock and pets, posted net income of $377 million, or 79 cents a share, in the second quarter, compared with $371 million, or 77 cents a share, in the comparable quarter last year.

Adjusted earnings were 89 cents a share, ahead of the 85 cents a share analysts polled by FactSet had expected.

Sales were about flat at $1.55 billion. Analysts were looking for $1.56 billion.

"Looking ahead, we expect our overall revenue growth for the remainder of the year to be driven largely by companion animal products, especially parasiticides and our key dermatology portfolio," Chief Executive Kristin Peck said.

The company now expects full-year earnings of $3.14 a share to $3.32 a share, or $3.52 a share to $3.68 a share on an adjusted basis. It previously expected earnings of $2.80 a share to $3.07 a share, or $3.17 a share to $3.42 a share on an adjusted basis.

Zoetis said it sees full-year revenue of $6.3 billion to $6.475 billion, up from its prior outlook of $5.95 billion to $6.25 billion.

Shares rose 3.7% to $163.48 in premarket trading.

Write to Dave Sebastian at dave.sebastian@wsj.com

(END) Dow Jones Newswires

August 06, 2020 07:55 ET (11:55 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.